Cynata Therapeutics Limited (CYYNF)
USD 0.3
(117.39%)
USD 0.3
(117.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.17 Million AUD | -48.19% |
| 2023 | 2.26 Million AUD | -12.66% |
| 2022 | 2.58 Million AUD | 61.57% |
| 2021 | 1.6 Million AUD | 132.23% |
| 2020 | 689.73 Thousand AUD | -46.04% |
| 2019 | 1.27 Million AUD | 71.32% |
| 2018 | 746.14 Thousand AUD | 91.52% |
| 2017 | 389.59 Thousand AUD | -12.92% |
| 2016 | 447.37 Thousand AUD | 19.18% |
| 2015 | 375.39 Thousand AUD | 426.53% |
| 2014 | 71.29 Thousand AUD | -52.37% |
| 2013 | 149.7 Thousand AUD | -8.21% |
| 2012 | 163.08 Thousand AUD | -33.68% |
| 2011 | 245.92 Thousand AUD | -22.37% |
| 2010 | 316.81 Thousand AUD | -30.87% |
| 2009 | 458.25 Thousand AUD | 292.08% |
| 2008 | 116.87 Thousand AUD | -20.58% |
| 2007 | 147.16 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 1.17 Million AUD | 0.0% |
| 2024 FY | 1.17 Million AUD | -48.19% |
| 2024 Q2 | 1.18 Million AUD | 0.0% |
| 2024 Q1 | 1.18 Million AUD | -54.33% |
| 2023 Q2 | 1.47 Million AUD | 0.0% |
| 2023 Q3 | 2.26 Million AUD | 52.89% |
| 2023 FY | 2.26 Million AUD | -12.66% |
| 2023 Q4 | 2.58 Million AUD | 14.5% |
| 2023 Q1 | 1.47 Million AUD | -42.87% |
| 2022 Q1 | 1.65 Million AUD | 3.62% |
| 2022 Q2 | 1.65 Million AUD | 0.0% |
| 2022 Q3 | 2.58 Million AUD | 55.92% |
| 2022 FY | 2.58 Million AUD | 61.57% |
| 2022 Q4 | 2.58 Million AUD | 0.0% |
| 2021 Q2 | 1.01 Million AUD | 0.0% |
| 2021 FY | 1.6 Million AUD | 132.23% |
| 2021 Q3 | 1.6 Million AUD | 58.15% |
| 2021 Q4 | 1.6 Million AUD | 0.0% |
| 2021 Q1 | 1.01 Million AUD | 46.84% |
| 2020 FY | 689.73 Thousand AUD | -46.04% |
| 2020 Q1 | 1.09 Million AUD | -14.39% |
| 2020 Q2 | 1.09 Million AUD | 0.0% |
| 2020 Q4 | 689.73 Thousand AUD | 0.0% |
| 2020 Q3 | 689.73 Thousand AUD | -36.97% |
| 2019 Q2 | 575.13 Thousand AUD | 0.0% |
| 2019 Q1 | 575.13 Thousand AUD | -22.92% |
| 2019 Q3 | 1.27 Million AUD | 122.26% |
| 2019 FY | 1.27 Million AUD | 71.32% |
| 2019 Q4 | 1.27 Million AUD | 0.0% |
| 2018 Q4 | 746.14 Thousand AUD | 0.0% |
| 2018 FY | 746.14 Thousand AUD | 91.52% |
| 2018 Q3 | 746.14 Thousand AUD | 122.81% |
| 2018 Q2 | 334.88 Thousand AUD | 0.0% |
| 2018 Q1 | 334.88 Thousand AUD | -14.04% |
| 2017 Q2 | 248.77 Thousand AUD | 0.0% |
| 2017 FY | 389.59 Thousand AUD | -12.92% |
| 2017 Q4 | 389.59 Thousand AUD | 0.0% |
| 2017 Q3 | 389.59 Thousand AUD | 56.61% |
| 2017 Q1 | 248.77 Thousand AUD | -44.39% |
| 2016 Q1 | 710.57 Thousand AUD | 89.29% |
| 2016 Q3 | 447.37 Thousand AUD | -37.04% |
| 2016 Q2 | 710.57 Thousand AUD | 0.0% |
| 2016 FY | 447.37 Thousand AUD | 19.18% |
| 2016 Q4 | 447.37 Thousand AUD | 0.0% |
| 2015 FY | 375.39 Thousand AUD | 426.53% |
| 2015 Q4 | 375.39 Thousand AUD | 0.0% |
| 2015 Q3 | 375.39 Thousand AUD | 81.38% |
| 2015 Q1 | 206.96 Thousand AUD | 190.29% |
| 2015 Q2 | 206.96 Thousand AUD | 0.0% |
| 2014 FY | 71.29 Thousand AUD | -52.37% |
| 2014 Q4 | 71.29 Thousand AUD | 0.0% |
| 2014 Q3 | 71.29 Thousand AUD | -68.45% |
| 2014 Q2 | 225.97 Thousand AUD | 0.0% |
| 2014 Q1 | 225.97 Thousand AUD | 50.95% |
| 2013 Q4 | 149.7 Thousand AUD | 0.0% |
| 2013 Q3 | 149.7 Thousand AUD | 0.0% |
| 2013 FY | 149.7 Thousand AUD | -8.21% |
| 2012 Q4 | 163.08 Thousand AUD | 0.0% |
| 2012 FY | 163.08 Thousand AUD | -33.68% |
| 2011 Q4 | 245.92 Thousand AUD | 0.0% |
| 2011 FY | 245.92 Thousand AUD | -22.37% |
| 2010 Q4 | 316.81 Thousand AUD | 0.0% |
| 2010 FY | 316.81 Thousand AUD | -30.87% |
| 2009 FY | 458.25 Thousand AUD | 292.08% |
| 2009 Q4 | 458.25 Thousand AUD | 0.0% |
| 2008 FY | 116.87 Thousand AUD | -20.58% |
| 2008 Q4 | 116.87 Thousand AUD | 0.0% |
| 2007 FY | 147.16 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.384% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 87.629% |
| CSL Limited | 18.62 Billion USD | 99.994% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.016% |
| Regen BioPharma, Inc. | 5.45 Million USD | 78.543% |
| BioStem Technologies, Inc. | 15.9 Million USD | 92.637% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.67% |
| Qrons Inc. | 1.48 Million USD | 21.338% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -44.79% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.437% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 93.637% |
| Skye Bioscience, Inc. | 14.07 Million USD | 91.678% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2520.044% |
| Rebus Holdings, Inc. | 5.24 Million USD | 77.66% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -482.278% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4168.782% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.912% |
| Neon Bloom, Inc. | 1.22 Million USD | 4.498% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.803% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 87.779% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -177.786% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.66% |
| Intellipharmaceutics International Inc. | 12 Million USD | 90.248% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 69.594% |
| Mesoblast Limited | 188.44 Million USD | 99.379% |
| Marizyme, Inc. | 26.67 Million USD | 95.61% |
| Genus plc | 485 Million USD | 99.759% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 79.957% |
| Pharming Group N.V. | 244.07 Million USD | 99.52% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 41.742% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 53.462% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 69.183% |
| ContraFect Corporation | 32.53 Million USD | 96.4% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 40.895% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 69.405% |
| IMV Inc. | 37.93 Million USD | 96.913% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 90.057% |
| MultiCell Technologies, Inc. | 1617.67 USD | -72291.464% |
| ONE Bio Corp. | 27.49 Million USD | 95.741% |
| Accustem Sciences Inc. | 1.07 Million USD | -8.507% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.487% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 44.633% |
| Q BioMed Inc. | 8.13 Million USD | 85.601% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.588% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 77.244% |
| Biomind Labs Inc. | 1.49 Million USD | 21.857% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.014% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 87.049% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 18.329% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -724.135% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 79.619% |
| GB Sciences, Inc. | 5.41 Million USD | 78.384% |
| Alpha Cognition Inc. | 7.16 Million USD | 83.655% |
| HST Global, Inc. | 593.59 Thousand USD | -97.282% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 7.0% |
| Halberd Corporation | 728.71 Thousand USD | -60.7% |
| Enzolytics Inc. | 365.26 Million USD | 99.679% |
| Agentix Corp. | 2.51 Million USD | 53.355% |
| Resverlogix Corp. | 67.39 Million USD | 98.262% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -39.622% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.737% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 31.677% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 95.268% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 90.162% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 68.049% |
| AVAX Technologies, Inc. | 3.99 Million USD | 70.678% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4147.724% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -390.692% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 68.641% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -72.003% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 56.814% |
| Kadimastem Ltd | 3.5 Million USD | 66.588% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1649.697% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -152.003% |
| LadRx Corporation | 2.2 Million USD | 46.783% |
| Cell Source, Inc. | 15.8 Million USD | 92.591% |
| Regen BioPharma, Inc. | 5.45 Million USD | 78.543% |
| NovAccess Global Inc. | 7.86 Million USD | 85.102% |
| Affymax, Inc. | 8.87 Million USD | 86.799% |
| Itoco Inc. | 1.65 Million USD | 29.162% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 42.919% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 80.641% |
| Mobile Lads Corp. | 1.31 Million USD | 10.844% |
| CytoDyn Inc. | 127.89 Million USD | 99.084% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2701.634% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 25.238% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 89.398% |
| SYBLEU INC | 681.41 Thousand USD | -71.857% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 80.808% |
| International Stem Cell Corporation | 5.27 Million USD | 77.808% |
| Bioxytran, Inc. | 3.24 Million USD | 63.962% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -87.127% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 74.637% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.143% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.74% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 42.181% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 78.623% |
| Neutra Corp. | 973.52 Thousand USD | -20.29% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.964% |
| PureTech Health plc | 125.58 Million USD | 99.068% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 68.831% |
| IXICO plc | 1.9 Million USD | 38.375% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 94.296% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.867% |
| CSL Limited | 18.62 Billion USD | 99.994% |
| Cellectis S.A. | 249.36 Million USD | 99.53% |